Titanium Dioxide

Summary

Titanium Dioxide (CHEMBL1201136) is an approved small molecule; indicated across 4 conditions including sunburn and skin neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201136
Name	Titanium Dioxide
Type	Small molecule
Max phase	4

Also known as: C.i. 77891, Ci 77891, CI-(1975)NO.77891, Ci-77891, Ci-pigment white 6, Dundee, E 171, E-171, E171, E45 sun, INS NO.171, INS-171

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
sunburn	4	MONDO:0005326	EFO:0003958
skin neoplasm	4	MONDO:0002531	MONDO:0002898
metabolic syndrome X	3	MONDO:0011565	EFO:0000195
urticaria	2	MONDO:0005492	EFO:0005531

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01021787	PHASE4	COMPLETED	Dermal Penetration of the Titanium Dioxide in Anthelios SX SPF40 Cream
NCT04365270	PHASE3	COMPLETED	Antibacterial Effect and Clinical Performance of Chitosan Modified Glass Ionomer
NCT00483496	PHASE2	COMPLETED	Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)
NCT02969720	Not specified	COMPLETED	Therapeutic Efficacy of Phytosterols on Metabolic Syndrome

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).